Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
Testosterone is covered by S1.1 of the effective 2026 WADA List and is prohibited in and out of competition. S1.1 applies to exogenous administration; its coverage is not limited to the named examples and includes relevant esters. [6]
S1.1; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and mechanism
Testosterone is an endogenous androgen used in replacement medicines. FDA’s current information page reports requested June 2026 changes to age-related hypogonadism and prostate-related labeling. That request is not proof that every individual product label has been updated. [4]
- Indication and availability must be checked for the particular formulation and country.
Human evidence
A randomized 10-week trial assigned 43 healthy men to testosterone or placebo, with or without resistance training. It found increases in muscle size and strength, especially with training. These short-term outcomes do not establish long-term safety or a suitable regimen. [2]
- Original trial abstract reviewed; complete paper not independently appraised.
Health risks
FDA’s 2025 review separated two findings: TRAVERSE did not identify a new major cardiovascular-event signal in its replacement-therapy population, while blood-pressure studies supported a class-wide warning. Neither finding establishes that high-dose, combined or unregulated androgen use is safe. [3] [4]
Unregulated product exposure
A 2024 analysis of 13 online SARM-marketed products found undeclared pharmaceuticals, including testosterone, in the sample set. [1]
- Small selected sample; it does not show that any particular current SARM product contains testosterone.
List year
The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [6] [7] [5]
- Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.
What remains uncertain
- This is a targeted source check, not a systematic review or independent clinical/regulatory sign-off. Uncited draft claims remain unpublished.
- Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- Illegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 38560649
- The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 8637535
- FDA issues class-wide labeling changes for testosterone products ↗Accessed 2026-11-10 · relevant primary-source text read
28 February 2025 notice; TRAVERSE and blood-pressure findings
- Testosterone Information ↗Accessed 2026-11-10 · relevant primary-source text read
Testosterone information; June 2026 requested label updates
- 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Resource description and effective date
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read
Introduction and S1, printed pages 3, 5–6
- WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Cover and S1, printed pages 1, 5–6
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.